Back to Search Start Over

Increased death and exhaustion of CD69high T cells and NK cells are associated with PD-1 antibody application in the in vitro co-culture system.

Authors :
Ying Wang
Zhengyi Sun
Xue Du
Qiuyang Yu
Chao Sun
Jing Huang
Liying Wang
Source :
PeerJ; May2023, p1-15, 15p
Publication Year :
2023

Abstract

Background: The application of PD-1 monoclonal antibody (mAb) helps to treat non-small cell lung cancer, but acquired resistance has emerged in clinical practice. We tested the hypothesis that acquired resistance of anti-PD-1 immunotherapy is linked to death and exhaustion of activated T and NK cell. Methods: The co-culture system of HCC827 cells and peripheral mononuclear cells (PBMCs) was established to evaluate the effect of PD-1 mAb on the death rate and exhaustion of T and NK cell. The predisposing role of CD69 for death and exhaustion was validated by using PHA-activated PBMCs of CD69<superscript>low</superscript> NSCLC patients. The 10- colour/three laser flow cytometer was used to test related markers for cell activation, death and exhaustion. Results: We found that PD-1 mAb increase the death and exhaustion of T cells and NK cells in a dose-dependent way when PBMCs from NSCLC patients whose the percentages of CD69<superscript>+</superscript> cells in peripheral blood T cells were greater than 5% (CD69<superscript>high</superscript> NSCLC patients). By analyzing PBMCs from healthy volunteers and CD69<superscript>low</superscript> NSCLC patients, we found that T cells and NK cells can be induced to die by PD-1 mAb after PHA activation, and had a tendency to raise the rate of cell exhaustion. Conclusions: Our findings imply that increased death and exhaustion of CD69<superscript>high</superscript> T cells and NK cells are associated with ineffective anti-PD-1 immunotherapy in lung cancer. The CD69 expression of T cells and NK cells may be developed as a potential predictor for acquired resistance of anti-PD-1 immunotherapy. These data may provide ideas to guide individualized medication of PD-1 mAb in NSCLC patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
21678359
Database :
Complementary Index
Journal :
PeerJ
Publication Type :
Academic Journal
Accession number :
164712700
Full Text :
https://doi.org/10.7717/peerj.15374